Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled thera...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2018-05-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/4/2/00119-2017.full |